Entries by CAPTIS

VBI Vaccines collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate

“COVID-19 is now the third, and to-date the most widespread, coronavirus outbreak in the 21st century, and while it is clearly a priority at this time, there remains The post VBI Vaccines collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate appeared first on Pharmaceutical Business review.

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

In January 2017, Daiichi Sankyo received exclusive development, manufacturing and commercialization rights for axicabtagene ciloleucel in Japan from California-based Kite, a Gilead Company. The Japan NDA submission is The post Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan appeared first on Pharmaceutical Business […]

Merck’s vericiguat meets primary endpoint in VICTORIA trial

Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisation or cardiovascular death, which was the primary endpoint The post Merck’s vericiguat meets primary endpoint in VICTORIA trial appeared first on Pharmaceutical Business review.

AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis

This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the The post AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis appeared first on Pharmaceutical Business review.